Xbrane Biopharma has announced that a Marketing Authorization Application (MAA) for biosimilar ranibizumab submitted by its co-development and commercialization partner, STADA Arzneimittel AG, has been validated by the European Medicines Agency (EMA).

Submission took place on September 9th and validation by EMA has now been communicated. The EMA validation confirms that the application is sufficiently complete to begin a formal review process. The company anticipates an EMA review for the biosimilar candidate, which was developed under the Xlucane name, will be according to standard timelines.

Xlucane

Xlucane is a biosimilar candidate to Lucentis (ranibizumab), a VEGF-a inhibitor used in treatment of serious eye diseases, mainly wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). A trade name under which the biosimilar, if approved, will be marketed will be announced later in regulatory review process.

“This marks yet another important milestone for Xbrane. The team, together with our colleagues at STADA, have worked relentlessly over recent months in preparing this filing. This milestone also represents a potentially important advancement for patients and families living with wet age-related degeneration as our ambition is that Xlucane shall provide a more cost-efficient alternative to current treatments,” says Xbrane CEO Martin Åmark.

Photo of Martin Åmark